Addressing Quality of Life, Clinical Outcomes, and Mechanisms in Uncontrolled Asthma Following the DASH Dietary Pattern

Last updated: July 7, 2024
Sponsor: University of Illinois at Chicago
Overall Status: Active - Recruiting

Phase

2/3

Condition

Asthma

Treatment

Group A - Patient Education

Group B - Patient Education with Nutrition Counseling

Clinical Study ID

NCT05251402
2021-1375
R61HL155160
  • Ages > 18
  • All Genders

Study Summary

The goal of the ALOHA trial is to investigate the efficacy of improved diet quality following a DASH behavioral intervention that has shown promising results in adults with uncontrolled asthma. DASH stands for Dietary Approaches to Stop Hypertension. This healthy diet is known to help people with high blood pressure manage their health. But physicians do not know if the DASH diet can also benefit patients with uncontrolled asthma. Researchers in the ALOHA study are trying to find out the answer to this important question.

Researchers at UIC are studying how 2 asthma care programs compare in terms of helping adults with uncontrolled asthma to improve their quality of life. Researchers also want to learn what might explain the differences in patient outcomes that they may see between the 2 programs.

The primary outcome will be asthma-specific quality of life. If the DASH behavioral intervention is found to benefit people with uncontrolled asthma, it would provide a practical, safe, and acceptable public-health intervention in the form of dietary modification to reduce the burden of asthma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 years or older at study enrollment

  • Diagnosis of asthma with currently prescribed controller therapy (i.e., Step 2 orabove) according to the 2020 asthma guideline update (EPR4)

  • Uncontrolled asthma on study screening based on Asthma Control Test (ACT) scores <20

  • Being able and willing to provide written informed consent and HIPAA authorization

Exclusion

Exclusion Criteria:

  • Inability to speak, read or understand English sufficiently to provide validinformed consent

  • Primary diagnosis of COPD (emphysema or chronic bronchitis)

  • Previous cardiovascular disease: coronary heart disease (myocardial infarction,angina pectoris, percutaneous coronary intervention, coronary artery bypass graftsurgery), cerebrovascular disease (stroke, transient ischemic attack), peripheralvascular disease, heart failure, or aortic aneurysm

  • Diabetes (other than during pregnancy)

  • Diagnosis of cancer (other than non-melanoma skin cancer) within the past yearand/or actively receiving cancer treatment

  • Inflammatory bowel disease, colostomy, malabsorption, or major gastrointestinalresection

  • Diagnosis of bipolar or psychotic disorder

  • Hospitalization for psychological or emotional problems within the last 2 years

  • Cognitive impairment based on the Callahan 6-item screener67

  • Terminal illness or in hospice or long-term care

  • Current diet of good quality (DASH concordance index ≥6 out of 9 total)

  • Current/planned participation in another structured program that overtly focuses ondiet and nutrition

  • On special diet that precludes changes adherent to the DASH dietary pattern orotherwise unwillingness to modify current diet

  • Current use of prescription or non-prescription weight-loss products andunwillingness to stop taking them for the duration of the study

  • Underweight per body mass index (BMI) below 18.5 kg/m2 based on measured height andweight at study enrollment

  • Actively attempting to lose weight or weight change >15 lbs during prior 3 months

  • Active alcohol or substance use disorder (including prescription drugs) based on theCAGE Questionnaire Adapted to Include Drugs (CAGE-AID)68

  • Current within the past 6-months or former smoker (more than 20-packs of cigarettesin the lifetime, or current smoker)

  • Current or planned pregnancy or currently lactating

  • Planning to move out of the area during the study period

  • Participation in another clinical trial or investigational treatment study

  • Family/household member of an already enrolled participant or of a study team member

  • Investigator discretion for clinical safety or protocol adherence reasons

Study Design

Total Participants: 320
Treatment Group(s): 2
Primary Treatment: Group A - Patient Education
Phase: 2/3
Study Start date:
March 09, 2022
Estimated Completion Date:
September 01, 2026

Study Description

Approximately 320 subjects who are determined fully eligible will be randomly assigned (by chance, like flipping a coin) to participate in intervention Group A or Group B, where you will receive either 1 of the 2 asthma care programs

Both asthma care programs are for a year and offer patient education on asthma and health. In both asthma care programs, you will receive fact-based patient information on asthma and health. Additionally, in one of the programs, a registered dietitian will also provide nutrition counseling on how to follow the USDA recommended DASH diet. Both asthma care programs offer 3 individual sessions, 8 group sessions, and 11 phone consultations. Your first individual session will be in-person with a trained health coach on the ALOHA team. The remaining 2 individual sessions will be either in-person or remote, depending on what you and your coach decide. You will also attend the first 2 (of 8) group sessions in-person to build connection with your coach and peer participants in the group. You and your coach will then decide whether you should attend the remaining group sessions in-person or remotely. Your ALOHA health coach will offer you continued support by phone until you complete your 1-year program.

Study Visits at UIC: Irrespective of your asthma care group, all participants will be expected to visit UIC Study site 4 times over the next year, initially and then at 3 months, at 6 months, and finally at one year. You will meet with an ALOHA study coordinator for 2 hours at the initial and final visits and for 1 hour at 3 and 6 months. Before each visit, you will complete online surveys about your health and phone interviews about your diet. At each visit, you will complete a breathing test, a blood draw, a physical exam, and questions about your asthma, diet and exercise habits, use of asthma medications and dietary supplements.

Connect with a study center

  • Department of Medicine

    Chicago, Illinois 60608
    United States

    Active - Recruiting

  • UIC CCTS Clinical Research Center

    Chicago, Illinois 60608
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.